fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ipratropium bromide

Form:

16 of 16 products shown

2 general benefit · 8 Limited Use · 6 not a benefit

PMS-Ipratropium · DIN 02239627 · 0.03% · Nasal Spray

Limited Use, Reason for Use code 03 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 03 required
Write on scriptReason for Use code 03 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 03
Reason for Use code 03 For the treatment of non-allergic vasomotor rhinitis Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
PMS-Ipratropium · DIN 02239627 Manufacturer: Pharmascience Inc.; listing date 2000-07-17 Health Canada: Marketed since 1999-04-15 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 21 MCG/ACT · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Ipratropium: Formulary list price $0.91 per unit (the source does not state the unit; exact figure $0.9127). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239627)

Source record
DIN 02239627: PMS-Ipratropium Raw flags: sec12=Y, sec3=Y Item: 523600082; group id 626; item number 1595; lccId 00088; manufacturer id PMS Source form: Nasal Spray; strength: 0.03% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.9127; ministry $0.9127 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239627 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63098
Interchangeable products
Atrovent · DIN 02163705 · not recorded
Shortage status: resolved shortage (ended January 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239627
Shortage record checked October 6, 2026

Atrovent HFA · DIN 02247686 · 20 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Atrovent HFA · DIN 02247686 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2004-11-04 Health Canada: Marketed since 2004-03-24 · brand ATROVENT HFA · ATC R03BB01 IPRATROPIUM BROMIDE · form Aerosol (metered-dose) · route Inhalation · ingredients IPRATROPIUM BROMIDE 20 MCG/ACT · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247686)

Source record
DIN 02247686: Atrovent HFA Raw flags: sec3=Y Item: 120800056; group id 207; item number 0377; lccId None; manufacturer id BOE Source form: Inh-200 Dose Pk; strength: 20mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $21.3600; ministry $11.2530 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247686 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71950
Interchangeable products
Jamp Ipratropium HFA · DIN 02542587 · $11.2530
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247686
Shortage record checked October 6, 2026

Jamp Ipratropium HFA · DIN 02542587 · 20 mcg/Metered Dose · inhaler, 200 doses

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Ipratropium HFA · DIN 02542587 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Marketed since 2024-08-15 · brand JAMP IPRATROPIUM HFA · ATC R03BB01 IPRATROPIUM BROMIDE · form Aerosol (metered-dose) · route Inhalation · ingredients IPRATROPIUM BROMIDE 20 MCG/ACT · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Ipratropium HFA: Formulary list price $11.25 per unit (the source does not state the unit; exact figure $11.2530). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02542587)

Source record
DIN 02542587: Jamp Ipratropium HFA Raw flags: sec3=Y Item: 120800056; group id 207; item number 0377; lccId None; manufacturer id JPC Source form: Inh-200 Dose Pk; strength: 20mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $11.2530; ministry $11.2530 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02542587 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103113
Interchangeable products
Atrovent HFA · DIN 02247686 · $11.2530
Shortage status: resolved shortage (ended June 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542587
Shortage record checked October 6, 2026

PMS-Ipratropium · DIN 02231135 · 125 mcg/mL · Inh Sol-2mL UDV Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231135 Manufacturer: Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 2001-06-08 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 125 MCG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Ipratropium: Formulary list price $1.15 per unit (the source does not state the unit; exact figure $1.1505). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231135)

Source record
DIN 02231135: PMS-Ipratropium Raw flags: sec12=Y, sec3=Y Item: 120800047; group id 206; item number 0375; lccId 00031; manufacturer id PMS Source form: Inh Sol-2mL UDV Pk; strength: 125mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1505; ministry $1.1505 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231135 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50442
Interchangeable products
Atrovent UDV · DIN 02026759 · not recorded
Shortage status: resolved shortage (ended August 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231135
Shortage record checked October 6, 2026

AA-Ipravent · DIN 02126222 · 250 mcg/mL · Inh Sol-20mL Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
AA-Ipravent · DIN 02126222 Manufacturer: A A Pharma Inc.; listing date 2000-11-30 Health Canada: Marketed since 2024-03-28 · brand AA-IPRAVENT · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Ipravent: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02126222)

Source record
DIN 02126222: AA-Ipravent Raw flags: sec12=Y, sec3=Y Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id AAP Source form: Inh Sol-20mL Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.3140; ministry $6.3140 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02126222 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16947
Interchangeable products
Atrovent · DIN 00731439 · not recorded Novo-Ipramide · DIN 02210479 · $6.3140 PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: resolved shortage (ended March 25, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02126222
Shortage record checked October 6, 2026

PMS-Ipratropium · DIN 02231245 · 250 mcg/mL · Inh Sol-2mL UDV Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231245 Manufacturer: Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 1997-10-29 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Ipratropium: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231245)

Source record
DIN 02231245: PMS-Ipratropium Raw flags: sec12=Y, sec3=Y Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id PMS Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3180; ministry $1.3180 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231245 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50552
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded Ratio-Ipratropium UDV · DIN 02097168 · $1.3180 Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: resolved shortage (ended November 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231245
Shortage record checked October 6, 2026

Teva-Ipratropium Sterinebs · DIN 02216221 · 250 mcg/mL · Inh Sol-2mL UDV Pk

Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Ipratropium Sterinebs · DIN 02216221 Manufacturer: Teva Canada Limited; listing date 1999-09-15 Health Canada: Marketed since 2012-07-12 · brand TEVA-IPRATROPIUM STERINEBS · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Ipratropium Sterinebs: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02216221)

Source record
DIN 02216221: Teva-Ipratropium Sterinebs Raw flags: sec12=Y, sec3=Y Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id TEV Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3180; ministry $1.3180 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216221 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43176
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded PMS-Ipratropium · DIN 02231245 · $1.3180 Ratio-Ipratropium UDV · DIN 02097168 · $1.3180
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02216221
Shortage record checked October 6, 2026

Ipravent · DIN 02246084 · 0.06% · Nasal Spray

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ipravent · DIN 02246084 Manufacturer: A A Pharma Inc.; listing date 2009-06-23 Health Canada: Marketed since 2014-05-28 · brand IPRAVENT · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 42 MCG/ACT · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246084)

Source record
DIN 02246084: Ipravent Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 523600117; group id 627; item number 1596; lccId None; manufacturer id AAP Source form: Nasal Spray; strength: 0.06% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.9700; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246084 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70219
Interchangeable products
Atrovent · DIN 02163713 · not recorded
Shortage status: active shortage (reported August 25, 2026, estimated to end October 30, 2026, last updated September 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246084
Shortage record checked October 6, 2026

PMS-Ipratropium · DIN 02231136 · 250 mcg/mL · Inh Sol-20mL Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredDormant since August 1, 2025 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Ipratropium · DIN 02231136 Manufacturer: Pharmascience Inc.; listing date 1999-04-15 Health Canada: Dormant since 2025-08-01 · brand PMS-IPRATROPIUM · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Ipratropium: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231136)

Source record
DIN 02231136: PMS-Ipratropium Raw flags: sec12=Y, sec3=Y Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id PMS Source form: Inh Sol-20mL Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.3140; ministry $6.3140 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231136 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50443
Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140 Atrovent · DIN 00731439 · not recorded Novo-Ipramide · DIN 02210479 · $6.3140
Shortage status: resolved shortage (ended June 26, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231136
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2025 — choose a marketed DIN from the same-category list.

Novo-Ipramide · DIN 02210479 · 250 mcg/mL · Inh Sol-20mL Pk

Limited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued October 26, 2015 · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below); Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Novo-Ipramide · DIN 02210479 Manufacturer: Novopharm Ltd.; listing date 1999-04-15 Health Canada: Cancelled post market since 2015-10-26 · brand NOVO-IPRAMIDE - LIQ 0.25MG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE .25 MG/ML · company Novopharm limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Novo-Ipramide: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02210479)

Source record
DIN 02210479: Novo-Ipramide Raw flags: sec12=Y, sec3=Y Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id NOP Source form: Inh Sol-20mL Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.3140; ministry $6.3140 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02210479 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20153
Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140 Atrovent · DIN 00731439 · not recorded PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02210479
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 26, 2015 — choose a marketed DIN from the same-category list.

Ratio-Ipratropium UDV · DIN 02097168 · 250 mcg/mL · Inh Sol-2mL UDV Pk

Limited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.Discontinued May 18, 2018 · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below); Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Ipratropium UDV · DIN 02097168 Manufacturer: Ratiopharm Inc.; listing date 1996-12-19 Health Canada: Cancelled post market since 2018-05-18 · brand RATIO-IPRATROPIUM UDV · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Ipratropium UDV: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02097168)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02097168). DIN 02097168: Ratio-Ipratropium UDV Raw flags: dinStatus=E, sec12=Y, sec3=Y Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id RPH Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed Source prices (unrounded): $1.3180; ministry $1.3180 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02097168 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19798
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded PMS-Ipratropium · DIN 02231245 · $1.3180 Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: resolved shortage (ended September 1, 2017); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02097168
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 18, 2018 — choose a marketed DIN from the same-category list.

Atrovent · DIN 02163705 · 0.03% · Nasal Spray

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.Discontinued November 13, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 03
Reason for Use code 03 For the treatment of non-allergic vasomotor rhinitis Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Atrovent · DIN 02163705 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-11-13 · brand ATROVENT NASAL SPRAY · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 21 MCG/ACT · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Atrovent: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163705)

Source record
DIN 02163705: Atrovent Raw flags: notABenefit=Y, sec3=Y Item: 523600082; group id 626; item number 1595; lccId 00088; manufacturer id BOE Source form: Nasal Spray; strength: 0.03% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163705 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19245
Interchangeable products
PMS-Ipratropium · DIN 02239627 · $0.9127
Shortage status: discontinued (October 4, 2018, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163705
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 13, 2018 — choose a marketed DIN from the same-category list.

Atrovent · DIN 02163713 · 0.06% · Nasal Spray

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.Discontinued November 13, 2018 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-11-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Atrovent · DIN 02163713 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2009-06-23 Health Canada: Cancelled post market since 2018-11-13 · brand ATROVENT NASAL SPRAY · ATC R01AX03 IPRATROPIUM BROMIDE · form Solution · route Nasal · ingredients IPRATROPIUM BROMIDE 42 MCG/ACT · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Atrovent: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163713)

Source record
DIN 02163713: Atrovent Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 523600117; group id 627; item number 1596; lccId None; manufacturer id BOE Source form: Nasal Spray; strength: 0.06% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163713 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19651
Interchangeable products
Ipravent · DIN 02246084 · not recorded
Shortage status: discontinued (November 13, 2018, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163713
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 13, 2018 — choose a marketed DIN from the same-category list.

Atrovent UDV · DIN 02026759 · 125 mcg/mL · Inh Sol-2mL UDV Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.Discontinued September 18, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-09-18 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent UDV · DIN 02026759 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-09-18 · brand ATROVENT UDV 125MCG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation, Oral · ingredients IPRATROPIUM BROMIDE 125 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Atrovent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02026759)

Source record
DIN 02026759: Atrovent UDV Raw flags: notABenefit=Y, sec3=Y Item: 120800047; group id 206; item number 0375; lccId 00031; manufacturer id BOE Source form: Inh Sol-2mL UDV Pk; strength: 125mcg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02026759 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14203
Interchangeable products
PMS-Ipratropium · DIN 02231135 · $1.1505
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02026759
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 18, 2008 — choose a marketed DIN from the same-category list.

Atrovent · DIN 00731439 · 250 mcg/mL · Inh Sol-20mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.Discontinued October 11, 2007 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-10-11 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent · DIN 00731439 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-10-11 · brand ATROVENT · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Atrovent: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00731439)

Source record
DIN 00731439: Atrovent Raw flags: notABenefit=Y, sec3=Y Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id BOE Source form: Inh Sol-20mL Pk; strength: 250mcg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00731439 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8525
Interchangeable products
AA-Ipravent · DIN 02126222 · $6.3140 Novo-Ipramide · DIN 02210479 · $6.3140 PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00731439
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 11, 2007 — choose a marketed DIN from the same-category list.

Atrovent UDV · DIN 01950681 · 250 mcg/mL · Inh Sol-2mL UDV Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.Discontinued April 16, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-04-16 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 265 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 266 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 267 Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 268 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Atrovent UDV · DIN 01950681 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-04-16 · brand ATROVENT UDV SOL INH 250MCG/ML · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Atrovent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01950681)

Source record
DIN 01950681: Atrovent UDV Raw flags: notABenefit=Y, sec3=Y Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id BOE Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01950681 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12454
Interchangeable products
PMS-Ipratropium · DIN 02231245 · $1.3180 Ratio-Ipratropium UDV · DIN 02097168 · $1.3180 Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01950681
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 16, 2008 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (R03BB): coverage varies; not interchangeable

  • Aclidinium (Tudorza Genuair): general benefit
  • Glycopyrronium (Seebri Breezhaler): general benefit
  • Tiotropium (Spiriva): general benefit
  • Umeclidinium (Incruse Ellipta): general benefit

Ipratropium bromide/salbutamol

2 Limited Use · 1 not a benefit

Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 Manufacturer: MDA Inc.; listing date 2019-12-20 Health Canada: Marketed since 2026-08-28 · brand IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Juno pharma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ipratropium Bromide and Salbutamol Sulph: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483394)

Source record
DIN 02483394: Ipratropium Bromide and Salbutamol Sulph Raw flags: sec12=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id MDI Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8066; ministry $0.8066 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483394 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384
Interchangeable products
Combivent UDV · DIN 02231675 · not recorded Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: resolved shortage (ended April 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483394
Shortage record checked October 6, 2026

Teva-Combo Sterinebs · DIN 02272695 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695 Manufacturer: Teva Canada Limited; listing date 2006-01-24 Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Combo Sterinebs: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272695)

Source record
DIN 02272695: Teva-Combo Sterinebs Raw flags: sec12=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8066; ministry $0.8066 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272695 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820
Interchangeable products
Combivent UDV · DIN 02231675 · not recorded Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked October 6, 2026

Combivent UDV · DIN 02231675 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.Discontinued January 8, 2020 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit: For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. Reason for Use code 256 Patients who have a tracheostomy; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 257 Patients with cystic fibrosis in whom nebulizer therapy is indicated; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 258 Patients with severe mental or physical disabilities; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 259 Patients who have previously used nebulizer therapy within the last 12 month period. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Combivent UDV · DIN 02231675 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1998-12-31 Health Canada: Cancelled post market since 2020-01-08 · brand COMBIVENT UDV · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Combivent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231675)

Source record
DIN 02231675: Combivent UDV Raw flags: notABenefit=Y, sec3=Y Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id BOE Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231675 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050
Interchangeable products
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066 Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: discontinued (January 8, 2020, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 8, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (R03BB): coverage varies; not interchangeable

  • Aclidinium (Tudorza Genuair): general benefit
  • Glycopyrronium (Seebri Breezhaler): general benefit
  • Tiotropium (Spiriva): general benefit
  • Umeclidinium (Incruse Ellipta): general benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 12:08:08 Antimuscarinics/Antispasmodics

TIOTROPIUM BROMIDE MONOHYDRATE

· 4 products · General benefit · strengths: 18mcg, 2.5mcg/Actuation · Inh Cap, Inh Sol-60 Actuation Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08:08 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

SODIUM CROMOGLYCATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 2% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AA-IPRAVENT (ipratropium bromide inhalation solution) is indicated for: • the treatment of bronchospasm associated with acute exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. • the treatment of bronchospasm associated with acute severe exacerbations of bronchial asthma when used in conjunction with a beta2 adrenergic agonist such as salbutamol. AA-IPRAVENT inhalation solution must be administered by means of nebulizer using gas flow (oxygen or compressed air). 1.1 Pediatrics Pediatrics (<5 years of age): Based on the data reviewed by Health Canada, the efficacy and safety of AA-IPRAVENT in children younger than 5 years have not been established. 1.2 Geriatrics Geriatrics (≥65 years of age): Elderly patients can use AA-IPRAVENT at the recommended dose. https://pdf.hres.ca/dpd_pm/00072339.PDF PM date: AUG 12, 1994 Source product: AA-IPRAVENT; DIN 02126222; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution in unit dose vials is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium and salbutamol. Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician. Administration should be stopped when sufficient symptom relief is achieved. Pediatrics: The efficacy and safety in children and adolescents under 18 years has not been established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation Solution is not indicated in this patient population. Geriatrics: Page 3 of 48 Elderly patients can use TEVA-COMBO Sterinebs® (s… https://pdf.hres.ca/dpd_pm/00033894.PDF PM date: March 1, 2016 Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ipravent · DIN 02246084 Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-30, last updated 2026-09-25); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246084

Check this DIN again

Atrovent · DIN 02163705 Shortage status: discontinued (2018-10-04, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163705

Check this DIN again

Atrovent · DIN 02163713 Shortage status: discontinued (2018-11-13, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163713

Check this DIN again

Combivent UDV · DIN 02231675 Shortage status: discontinued (2020-01-08, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231675

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Ipravent, Atrovent, Atrovent UDV, Combivent UDV: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026